Want to join the conversation?
Pharmaceutical company $REGN said it presented positive preliminary results from the proof-of-concept study of evinacumab in patients with Homozygous Familial Hypercholestrolemia. The interim data showed that evinacumab added to current lipid-lowering therapy reduced low-density lipoprotein cholesterol levels by 55% versus baseline.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)